Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Rating of “Buy” from Analysts

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) has been given an average rating of “Buy” by the seven ratings firms that are currently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $9.05.

Several research firms have issued reports on CMPX. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Compass Therapeutics in a report on Thursday. EF Hutton Acquisition Co. I began coverage on shares of Compass Therapeutics in a research note on Friday, December 16th. They issued a “buy” rating and a $10.30 price objective for the company. Stifel Nicolaus started coverage on shares of Compass Therapeutics in a research note on Thursday, January 26th. They set a “buy” rating and a $9.00 target price on the stock. Finally, Jefferies Financial Group started coverage on Compass Therapeutics in a research report on Tuesday, January 31st. They issued a “buy” rating and a $8.00 target price for the company.

Insider Activity at Compass Therapeutics

In other news, CEO Thomas J. Schuetz purchased 20,000 shares of the stock in a transaction that occurred on Tuesday, January 31st. The stock was acquired at an average price of $4.05 per share, with a total value of $81,000.00. Following the purchase, the chief executive officer now owns 5,471,873 shares in the company, valued at approximately $22,161,085.65. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Compass Therapeutics news, CEO Thomas J. Schuetz bought 20,000 shares of the stock in a transaction on Tuesday, January 31st. The shares were purchased at an average cost of $4.05 per share, with a total value of $81,000.00. Following the completion of the transaction, the chief executive officer now directly owns 5,471,873 shares of the company’s stock, valued at approximately $22,161,085.65. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Thomas J. Schuetz purchased 10,000 shares of Compass Therapeutics stock in a transaction on Friday, March 10th. The stock was bought at an average cost of $3.37 per share, with a total value of $33,700.00. Following the transaction, the chief executive officer now directly owns 6,021,873 shares of the company’s stock, valued at $20,293,712.01. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 90,000 shares of company stock valued at $355,300. Insiders own 29.80% of the company’s stock.

Hedge Funds Weigh In On Compass Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Braidwell LP bought a new position in Compass Therapeutics in the 4th quarter worth $9,126,000. Vivo Capital LLC lifted its position in shares of Compass Therapeutics by 77.9% during the 4th quarter. Vivo Capital LLC now owns 3,557,630 shares of the company’s stock worth $17,895,000 after purchasing an additional 1,557,630 shares during the last quarter. Eventide Asset Management LLC bought a new stake in Compass Therapeutics during the 3rd quarter valued at approximately $2,509,000. Monashee Investment Management LLC grew its holdings in Compass Therapeutics by 81.3% in the 4th quarter. Monashee Investment Management LLC now owns 2,230,441 shares of the company’s stock valued at $11,219,000 after buying an additional 1,000,000 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in Compass Therapeutics by 58.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,380,623 shares of the company’s stock worth $5,428,000 after buying an additional 878,650 shares during the period. Institutional investors and hedge funds own 54.27% of the company’s stock.

Compass Therapeutics Stock Down 3.9 %

Shares of NASDAQ CMPX opened at $3.42 on Friday. Compass Therapeutics has a 52-week low of $1.25 and a 52-week high of $5.65. The stock has a market capitalization of $431.57 million, a price-to-earnings ratio of -8.14 and a beta of 0.93. The stock’s fifty day simple moving average is $4.04 and its 200 day simple moving average is $3.84.

About Compass Therapeutics

(Get Rating)

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137.